Literature DB >> 10490623

Controlled dimerization of ErbB receptors provides evidence for differential signaling by homo- and heterodimers.

S K Muthuswamy1, M Gilman, J S Brugge.   

Abstract

The four members of the ErbB family of receptor tyrosine kinases are involved in a complex array of combinatorial interactions involving homo- and heterodimers. Since most cell types express more than one member of the ErbB family, it is difficult to distinguish the biological activities of different homo- and heterodimers. Here we describe a method for inducing homo- or heterodimerization of ErbB receptors by using synthetic ligands without interference from the endogenous receptors. ErbB receptor chimeras containing synthetic ligand binding domains (FK506-binding protein [FKBP] or FKBP-rapamycin-binding domain [FRB]) were homodimerized with the bivalent FKBP ligand AP1510 and heterodimerized with the bifunctional FKBP-FRB ligand rapamycin. AP1510 treatment induced tyrosine phosphorylation of ErbB1 and ErbB2 homodimers and recruitment of Src homology 2 domain-containing proteins (Shc and Grb2). In addition, ErbB1 and ErbB2 homodimers activated downstream signaling pathways leading to Erk2 and Akt phosphorylation. However, only ErbB1 homodimers were internalized upon AP1510 stimulation, and only ErbB1 homodimers were able to associate with and induce phosphorylation of c-Cbl. Cells expressing AP1510-induced ErbB1 homodimers were able to associate with and induce phosphorylation of c-Cbl. Cells expressing AP1510-induced ErbB1 homodimers were able to form foci; however, cells expressing ErbB2 homodimers displayed a five- to sevenfold higher focus-forming ability. Using rapamycin-inducible heterodimerization we show that c-Cbl is unable to associate with ErbB1 in a ErbB1-ErbB2 heterodimer most likely because ErbB2 is unable to phosphorylate the c-Cbl binding site on ErbB1. Thus, we demonstrate that ErbB1 and ErbB2 homodimers differ in their abilities to transform fibroblasts and provide evidence for differential signaling by ErbB homodimers and heterodimers. These observations also validate the use of synthetic ligands to study the signaling and biological specificity of selected ErbB dimers in any cell type.

Entities:  

Mesh:

Substances:

Year:  1999        PMID: 10490623      PMCID: PMC84681          DOI: 10.1128/MCB.19.10.6845

Source DB:  PubMed          Journal:  Mol Cell Biol        ISSN: 0270-7306            Impact factor:   4.272


  80 in total

1.  Dimerization of the p185neu transmembrane domain is necessary but not sufficient for transformation.

Authors:  C L Burke; M A Lemmon; B A Coren; D M Engelman; D F Stern
Journal:  Oncogene       Date:  1997-02-13       Impact factor: 9.867

2.  Dimeric ligands define a role for transcriptional activation domains in reinitiation.

Authors:  S N Ho; S R Biggar; D M Spencer; S L Schreiber; G R Crabtree
Journal:  Nature       Date:  1996-08-29       Impact factor: 49.962

Review 3.  Creating conditional mutations in mammals.

Authors:  D M Spencer
Journal:  Trends Genet       Date:  1996-05       Impact factor: 11.639

4.  Signal transduction in T lymphocytes using a conditional allele of Sos.

Authors:  L J Holsinger; D M Spencer; D J Austin; S L Schreiber; G R Crabtree
Journal:  Proc Natl Acad Sci U S A       Date:  1995-10-10       Impact factor: 11.205

5.  A humanized system for pharmacologic control of gene expression.

Authors:  V M Rivera; T Clackson; S Natesan; R Pollock; J F Amara; T Keenan; S R Magari; T Phillips; N L Courage; F Cerasoli; D A Holt; M Gilman
Journal:  Nat Med       Date:  1996-09       Impact factor: 53.440

6.  Association of csk-homologous kinase (CHK) (formerly MATK) with HER-2/ErbB-2 in breast cancer cells.

Authors:  S Zrihan-Licht; J Lim; I Keydar; M X Sliwkowski; J E Groopman; H Avraham
Journal:  J Biol Chem       Date:  1997-01-17       Impact factor: 5.157

7.  Functional analysis of Fas signaling in vivo using synthetic inducers of dimerization.

Authors:  D M Spencer; P J Belshaw; L Chen; S N Ho; F Randazzo; G R Crabtree; S L Schreiber
Journal:  Curr Biol       Date:  1996-07-01       Impact factor: 10.834

8.  A hierarchical network of interreceptor interactions determines signal transduction by Neu differentiation factor/neuregulin and epidermal growth factor.

Authors:  E Tzahar; H Waterman; X Chen; G Levkowitz; D Karunagaran; S Lavi; B J Ratzkin; Y Yarden
Journal:  Mol Cell Biol       Date:  1996-10       Impact factor: 4.272

9.  Coupling of the c-Cbl protooncogene product to ErbB-1/EGF-receptor but not to other ErbB proteins.

Authors:  G Levkowitz; L N Klapper; E Tzahar; A Freywald; M Sela; Y Yarden
Journal:  Oncogene       Date:  1996-03-07       Impact factor: 9.867

10.  Mutations affecting conserved cysteine residues within the extracellular domain of Neu promote receptor dimerization and activation.

Authors:  P M Siegel; W J Muller
Journal:  Proc Natl Acad Sci U S A       Date:  1996-08-20       Impact factor: 11.205

View more
  134 in total

Review 1.  ErbB-4: a receptor tyrosine kinase.

Authors:  W Zhou; G Carpenter
Journal:  Inflamm Res       Date:  2002-02       Impact factor: 4.575

2.  Protein-protein interactions monitored in mammalian cells via complementation of beta -lactamase enzyme fragments.

Authors:  Tom Wehrman; Benjamin Kleaveland; Jeng-Horng Her; Robert F Balint; Helen M Blau
Journal:  Proc Natl Acad Sci U S A       Date:  2002-03-19       Impact factor: 11.205

3.  Allosteric activation of kinases: design and application of RapR kinases.

Authors:  Andrei V Karginov; Klaus M Hahn
Journal:  Curr Protoc Cell Biol       Date:  2011-12

4.  Lhx3 is required to maintain cancer cell development of high-grade oligodendroglioma.

Authors:  Hongliang Liu; Wei Liu; Bin Zhu; Qiang Xu; Xiaowei Ni; Ji Yu
Journal:  Mol Cell Biochem       Date:  2014-11-16       Impact factor: 3.396

5.  Receptor activity-independent recruitment of betaarrestin2 reveals specific signalling modes.

Authors:  Sonia Terrillon; Michel Bouvier
Journal:  EMBO J       Date:  2004-09-23       Impact factor: 11.598

Review 6.  Cbl and human myeloid neoplasms: the Cbl oncogene comes of age.

Authors:  Stephen C Kales; Philip E Ryan; Marion M Nau; Stanley Lipkowitz
Journal:  Cancer Res       Date:  2010-05-25       Impact factor: 12.701

7.  Chaperone-dependent E3 ubiquitin ligase CHIP mediates a degradative pathway for c-ErbB2/Neu.

Authors:  Wanping Xu; Monica Marcu; Xitong Yuan; Edward Mimnaugh; Cam Patterson; Len Neckers
Journal:  Proc Natl Acad Sci U S A       Date:  2002-09-18       Impact factor: 11.205

Review 8.  The oncogene HER2: its signaling and transforming functions and its role in human cancer pathogenesis.

Authors:  M M Moasser
Journal:  Oncogene       Date:  2007-04-30       Impact factor: 9.867

9.  Cardiac toxicity and efficacy of trastuzumab combined with pertuzumab in patients with [corrected] human epidermal growth factor receptor 2-positive metastatic breast cancer.

Authors:  Chia C Portera; Janice M Walshe; Douglas R Rosing; Neelima Denduluri; Arlene W Berman; Ujala Vatas; Margarita Velarde; Catherine K Chow; Seth M Steinberg; Diana Nguyen; Sherry X Yang; Sandra M Swain
Journal:  Clin Cancer Res       Date:  2008-05-01       Impact factor: 12.531

10.  Rational design of novel antiandrogens for neutralizing androgen receptor function in hormone refractory prostate cancer.

Authors:  Pratap Singh; Gurulingappa Hallur; Ravi K Anchoori; Oladapo Bakare; Yukio Kageyama; Saeed R Khan; John T Isaacs
Journal:  Prostate       Date:  2008-10-01       Impact factor: 4.104

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.